IOWA

National Museum of the Surface Navy Selects Lockheed Martin's Stephanie C. Hill to Receive the 2023 Vice Admiral Samuel L. Gravely, Jr., Leadership Award

Retrieved on: 
Tuesday, September 12, 2023

SAN PEDRO, Calif., Sept. 12, 2023 /PRNewswire-PRWeb/ -- The National Museum of the Surface Navy (NMSN) has selected Ms. Stephanie C. Hill – executive vice president, Rotary and Mission Systems at Lockheed Martin – as the recipient of the 2023 Vice Admiral (VADM) Samuel L. Gravely, Jr., Leadership Award.

Key Points: 
  • Stephanie C. Hill, executive vice president, Rotary and Mission Systems at Lockheed Martin, has been named the recipient of the 2023 Vice Admiral Samuel L. Gravely, Jr., Leadership Award by the National Museum of the Surface Navy.
  • SAN PEDRO, Calif., Sept. 12, 2023 /PRNewswire-PRWeb/ -- The National Museum of the Surface Navy (NMSN) has selected Ms. Stephanie C. Hill – executive vice president, Rotary and Mission Systems at Lockheed Martin – as the recipient of the 2023 Vice Admiral (VADM) Samuel L. Gravely, Jr., Leadership Award.
  • "Stephanie Hill's commitment to supporting our nation's sailors, as well as her career and personal achievements, have been broadly recognized nationwide.
  • She represents the profound and lasting impact VADM Gravely had within our great U.S. Navy and on our wonderful nation."

Lockheed Martin Skunk Works® and University of Iowa Successfully Demonstrate Artificial Intelligence-Commanded Mission

Retrieved on: 
Monday, September 11, 2023

This project, named Enhanced Collaborative High-Frequency Orientation System (ECHOS), was sponsored by Lockheed Martin's 21st Century Security Demonstrations & Prototypes (D&P) organization.

Key Points: 
  • This project, named Enhanced Collaborative High-Frequency Orientation System (ECHOS), was sponsored by Lockheed Martin's 21st Century Security Demonstrations & Prototypes (D&P) organization.
  • The L-29s were flown by experienced OPL pilots, following instructions from the AI agents in the form of heading, altitude, and speed cues.
  • Demonstrating how AI can provide data for rapid decision making and increased mission effectiveness by reducing pilot workload.
  • Agents were able to learn these tactics with sparse rewards, ensuring the best possible tactics for the mission were executed.

Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

Retrieved on: 
Wednesday, August 30, 2023

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two presentations at the upcoming World Molecular Imaging Congress (WMIC) 2023, hosted by the World Molecular Imaging Society (WMIS).

Key Points: 
  • RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two presentations at the upcoming World Molecular Imaging Congress (WMIC) 2023, hosted by the World Molecular Imaging Society (WMIS).
  • “We are pleased with our team’s progress in pioneering the development of promising image-guided, lead-based, alpha particle therapies.” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • Presenter: Michael K. Schultz, Ph.D., chief scientific officer, Perspective Therapeutics on behalf of Major Dr. Dongyoul Lee PhD, Assistant Professor, Korean Military Academy, Seoul, South Korea.
  • Additionally, a copy of the abstracts will be available on the Publications page of the Perspective Therapeutics website following the conference.

Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, August 28, 2023

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).

Key Points: 
  • RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).
  • “Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • “We are particularly excited about the early clinical results from 212Pb-VMT-α-NET in patients suffering from different types of difficult-to-treat neuroendocrine tumors.
  • The data showed that fractionated doses of [212Pb]VMT-α-NET provided greater benefit than single dose administration of [212Pb]VMT-α-NET.

Battleship USS IOWA Education Programs Leverage Historical Battleship to Bring STEM Lessons to LIfe

Retrieved on: 
Wednesday, July 26, 2023

SAN PEDRO, Calif., July 26, 2023 /PRNewswire-PRWeb/ -- Battleship USS IOWA Museum, a top five museum and attraction in the Los Angeles area and future home of the National Museum of the Surface Navy, today announced the availability of unique, interactive education programs that combine history with STEM education. Offered in both in-person and virtual formats, the STEAM at Sea program is designed to engage students in grades 2-8 in a variety of scientific and engineering concepts that can be related to Battleship USS IOWA.

Key Points: 
  • The historic battleship was relocated to her current berth in San Pedro, Calif., and opened to the public on July 4, 2012, as Battleship USS IOWA Museum, where she now serves as a community platform for education, veterans, and the community.
  • The Battleship IOWA education team provides synchronous virtual lessons that include a Powerpoint presentation designed with inquiry-based learning in mind to engage students and encourage discussion.
  • The schedule and pricing for upcoming sessions can be found on the Battleship IOWA education program page.
  • For more information about the education programs offered year-round aboard Battleship USS IOWA, visit the Education Programs page on the website, or contact Education Manager Tiffany Ellerbeck at [email protected] or 877-446-9261 ext.

IOTAMOTION COMPLETES $12M SERIES A RAISE TO ACCELERATE COMMERCIAL EXPANSION OF IOTASOFT® INSERTION SYSTEM

Retrieved on: 
Wednesday, July 26, 2023

The company closed the round with support from a select group of venture capital firms, private investors, and current shareholders.

Key Points: 
  • The company closed the round with support from a select group of venture capital firms, private investors, and current shareholders.
  • The lead investor was Research Corporation Technologies, Inc. (RCT) with participation from Mutual Capital Partners, ISA Ventures, and Next Level Ventures.
  • The capital raised in the Series A round will fuel commercial expansion of the iotaSOFT® Insertion System, which continued to gain momentum in the first half of 2023, and drive new innovations in robotic-assisted cochlear implantation.
  • iotaMotion continues to drive adoption of the iotaSOFT Insertion System through an expanded commercial release with systems distributed across the country.

MidWestOne Financial Group, Inc. Announces Second Quarter 2023 Earnings Conference Call

Retrieved on: 
Monday, July 24, 2023

IOWA CITY, Iowa, July 24, 2023 (GLOBE NEWSWIRE) -- MidWestOne Financial Group, Inc. (Nasdaq: MOFG) (“MidWestOne” or the “Company”), parent company of MidWestOne Bank, today announced that its second quarter 2023 financial results will be released before market open on Tuesday, August 1, 2023. The Company will host a conference call to discuss its financial results at 11:00 a.m. Central Time on Tuesday, August 1, 2023.

Key Points: 
  • IOWA CITY, Iowa, July 24, 2023 (GLOBE NEWSWIRE) -- MidWestOne Financial Group, Inc. (Nasdaq: MOFG) (“MidWestOne” or the “Company”), parent company of MidWestOne Bank, today announced that its second quarter 2023 financial results will be released before market open on Tuesday, August 1, 2023.
  • The Company will host a conference call to discuss its financial results at 11:00 a.m. Central Time on Tuesday, August 1, 2023.
  • Investors and analysts interested in participating in the call may pre-register utilizing the following link: https://www.netroadshow.com/events/login?show=c7140c96&confId=51647 .
  • A live audio webcast of the conference call can be accessed through the Investor Relations section of the Company’s website at https://www.midwestonefinancial.com .

Perspective Therapeutics’ Cesium-131 Featured at the American Brachytherapy Society’s Annual Conference

Retrieved on: 
Tuesday, June 27, 2023

RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer was presented at the recent American Brachytherapy Society’s (ABS) annual conference held in Vancouver, British Columbia, Canada from June 21-24, 2023.

Key Points: 
  • RICHLAND, WASHINGTON & CORALVILLE, IOWA, June 27, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed brachytherapy treatment options for multiple cancers, today announced that long term data regarding Cesium-131 brachytherapy in the treatment of prostate cancer was presented at the recent American Brachytherapy Society’s (ABS) annual conference held in Vancouver, British Columbia, Canada from June 21-24, 2023.
  • The authors reported that Cesium-131 prostate brachytherapy provided disease-free survival rates of 97.8% and 96%, at 5 and 10 years respectively.
  • “We’re excited that a presentation of long-term clinical data on Cesium-131 brachytherapy for prostate cancer was included at this year’s ABS meeting,” said Thijs Spoor, Perspective’s Chief Executive Officer.
  • He added, “The data shows Cesium-131 brachytherapy offers prostate cancer patients the prospect of disease-free survival of 96% ten years after treatment.

Perspective Therapeutics Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Retrieved on: 
Wednesday, June 21, 2023

The first product candidate, VMT-α-NET, is a result of Perspective’s intensive in-house research and development efforts to develop a best-in-class radiopeptide.

Key Points: 
  • The first product candidate, VMT-α-NET, is a result of Perspective’s intensive in-house research and development efforts to develop a best-in-class radiopeptide.
  • Both US trials will be supplied with finished drug product from Perspective’s GMP manufacturing facility in Coralville, IA.
  • “These clinical trials represent a significant advancement in our relentless pursuit of innovative and potent treatments for cancer," said Markus Puhlmann, Chief Medical Officer at Perspective.
  • The targeted alpha-particle therapies that are being developed at Perspective have the potential to revolutionize the treatment of these and many other cancers.

Perspective Therapeutics’ Cesium-131 to be Featured in Presentations at the 2023 American Brachytherapy Society’s Annual Meeting

Retrieved on: 
Friday, June 16, 2023

“We are delighted that long-term clinical data on the benefits of Cesium-131 brachytherapy for prostate cancer will be presented at this year’s ABS Annual Meeting,” said Thijs Spoor, Perspective Therapeutics’ Chief Executive Officer.

Key Points: 
  • “We are delighted that long-term clinical data on the benefits of Cesium-131 brachytherapy for prostate cancer will be presented at this year’s ABS Annual Meeting,” said Thijs Spoor, Perspective Therapeutics’ Chief Executive Officer.
  • He added, “We’re also excited to note that the American Brachytherapy Society is including a session entitled, ‘Implementation of Radiopharmaceuticals in the Radiation Oncology Clinic’.
  • Dr. Smith has extensive experience with Cesium-131 brachytherapy for prostate cancer and has treated over 1,000 patients at UPMC.
  • Andrew Bright, Perspective Therapeutics’ EVP of Brachytherapy, added, “Long-term outcomes have already demonstrated the significance of Cesium-131 brachytherapy for prostate cancer treatment.